Core Insights - Novo Nordisk has terminated its collaboration with Hims & Hers Health, Inc. due to non-compliance with legal standards regarding the sale of compounded drugs, which poses risks to patient safety [1][2][8] - The FDA has confirmed that Novo Nordisk is meeting the current and projected demand for Wegovy®, resolving previous shortages [2] - Novo Nordisk emphasizes the importance of providing authentic, FDA-approved Wegovy® to patients and is committed to working with telehealth companies that prioritize patient safety [3][8] Company Actions - Novo Nordisk will no longer provide Wegovy® through Hims & Hers Health, Inc. due to their deceptive marketing practices and illegal sales of compounded drugs [1][2][8] - The company is taking proactive measures to protect U.S. patients from unsafe knock-off drugs made with illicit foreign ingredients, particularly those sourced from unapproved suppliers in China [3][8] - Novo Nordisk aims to ensure that patients receive authentic Wegovy® through NovoCare® Pharmacy, which offers home delivery and support services [6][8] Industry Context - Obesity is recognized as a serious chronic disease affecting approximately 40% of adults in the U.S., necessitating long-term management and treatment options [5][23] - The prevalence of obesity has significant implications for healthcare systems, highlighting the need for effective and safe treatment options like Wegovy® [5][23] - The collaboration between telehealth companies and pharmaceutical firms is critical in providing access to regulated medications, but must adhere to legal and safety standards to protect patients [2][3][8]